Publication
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (10)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 10
- cancerMalignant Colorectal Neoplasmcivic_curation1.00
- cancerMelanomacivic_curation1.00
- cancerUveal Melanomacivic_curation1.00
- drugRefametinibcivic_curation1.00
- geneBRAFcivic_curation1.00
- geneGNAQcivic_curation1.00
- geneKRAScivic_curation1.00
- variantBRAF V600civic_curation1.00
- variantGNAQ Q209civic_curation1.00
- variantKRAS Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23434733
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KRAS Mutation1 | ||||||||
| Refametinib | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | C | Does Not Support Sensitivity Response | 2 | accepted | EID1001Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 4 patients with KRAS +/- PIK3CA mutant colorectal cancer. 3 with SD, 1 with PD. PMID 23434733 · Weekes et al., 2013 · Open in CIViC | civic |
| BRAF V6001 | ||||||||
| Refametinib | Melanoma | Predictive | C | Supports Resistance | 2 | accepted | EID1000Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 2 of 2 patients with BRAF mutant melanoma had moderate progressive disease (despite receiving the highest doses adminis… (full text at CIViC) PMID 23434733 · Weekes et al., 2013 · Open in CIViC | civic |
| GNAQ Q2091 | ||||||||
| Refametinib | Uveal Melanoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1233Phase 1 study of MAPK1/2 inhibitor BAY 86-9766. 53 patients were evaluated for efficacy, one patients achieved a PR and 11 patients had stable disease. One ocular melanoma patient with prolonged stabl… (full text at CIViC) PMID 23434733 · Weekes et al., 2013 · Open in CIViC | civic |